MX2023011807A - Metodos para controlar la actividad de las celulas inmunitarias. - Google Patents

Metodos para controlar la actividad de las celulas inmunitarias.

Info

Publication number
MX2023011807A
MX2023011807A MX2023011807A MX2023011807A MX2023011807A MX 2023011807 A MX2023011807 A MX 2023011807A MX 2023011807 A MX2023011807 A MX 2023011807A MX 2023011807 A MX2023011807 A MX 2023011807A MX 2023011807 A MX2023011807 A MX 2023011807A
Authority
MX
Mexico
Prior art keywords
activity
immunotherapeutic agent
target antigen
cellular immunotherapeutic
methods
Prior art date
Application number
MX2023011807A
Other languages
English (en)
Spanish (es)
Inventor
Julian Alexander Barden
Ziduo Li
Patrick Schlegel
Original Assignee
Biosceptre Aust Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901030A external-priority patent/AU2021901030A0/en
Application filed by Biosceptre Aust Pty Ltd filed Critical Biosceptre Aust Pty Ltd
Publication of MX2023011807A publication Critical patent/MX2023011807A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023011807A 2021-04-08 2022-04-08 Metodos para controlar la actividad de las celulas inmunitarias. MX2023011807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2021901030A AU2021901030A0 (en) 2021-04-08 Methods for controlling immune cell activity
PCT/AU2022/050311 WO2022213154A1 (en) 2021-04-08 2022-04-08 Methods for controlling immune cell activity

Publications (1)

Publication Number Publication Date
MX2023011807A true MX2023011807A (es) 2024-01-05

Family

ID=83544929

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011807A MX2023011807A (es) 2021-04-08 2022-04-08 Metodos para controlar la actividad de las celulas inmunitarias.

Country Status (9)

Country Link
US (1) US20250282844A1 (enExample)
EP (1) EP4319793A4 (enExample)
JP (1) JP2024513485A (enExample)
CN (1) CN117157092A (enExample)
AU (1) AU2022253547A1 (enExample)
BR (1) BR112023020659A2 (enExample)
CA (1) CA3213042A1 (enExample)
MX (1) MX2023011807A (enExample)
WO (1) WO2022213154A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026507807A (ja) * 2023-03-08 2026-03-06 バイオセプター （オースト） プロプライエタリー・リミテッド 機能不全ｐ２ｘ７受容体に結合するためのキメラ抗原受容体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101555283B (zh) * 2001-01-17 2012-03-21 生物权威国际有限公司 针对非功能性p2x7受体的抗体及其在癌症和其它病情的诊断和治疗中的用途
WO2003020762A1 (en) * 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
AU2009266430B2 (en) * 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
EP3484455A2 (en) * 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US10986601B2 (en) * 2017-07-26 2021-04-20 Panoramic Power Ltd. System and method for timing synchronization of a self-powered power sensor
CA3211323A1 (en) * 2021-03-11 2022-09-15 Patrick Schlegel Novel cell therapy system

Also Published As

Publication number Publication date
WO2022213154A1 (en) 2022-10-13
US20250282844A1 (en) 2025-09-11
EP4319793A4 (en) 2025-03-19
AU2022253547A1 (en) 2023-10-05
BR112023020659A2 (pt) 2023-12-05
JP2024513485A (ja) 2024-03-25
CA3213042A1 (en) 2022-10-13
CN117157092A (zh) 2023-12-01
EP4319793A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
CO2022013525A2 (es) Anticuerpos contra sars-cov-2 y métodos para usarlos
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
CL2020000919A1 (es) Anticuerpos específicos cd47/pd-l1.
CO2022017670A2 (es) Anticuerpos contra sars-cov-2
DOP2020000128A (es) Anticuerpos anti-trem2 y métodos relacionados
CL2018003407A1 (es) Anticuerdos anti-pd-1, método para producir el mismo y método para usar el mismo.
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
MX2020011744A (es) Molecula de polipeptido con especificidad dual mejorada.
CL2024002093A1 (es) Anticuerpos anti-cd73.
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
CO2017001023A2 (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
AR106201A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
BR112022020256A2 (pt) “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
CL2018002994A1 (es) Inmunoterapia para cáncer mediante activación inmunológica o modulación inmunológica a través de antígenos de la serie globo.
MX2022007107A (es) Composiciones celulares terapeuticas y metodos de preparacion y usos de las mismas.
MX2022003668A (es) Metodos y composiciones para el tratamiento de la retinopatia diabetica.
SA519401032B1 (ar) (pd-1) جسم مضاد لموت الخلية المبرمج1 واستخدامه
MX2020008801A (es) Células presentadoras de antígeno universal y usos de las mismas.
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
BR112023020303A2 (pt) Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
EP4653465A3 (en) Methods of reversing ticagrelor activity
MX2025004503A (es) Productos de anticuerpos contra el receptor tipo inmunoglobulina leucocitaria b2 (lilrb2) y metodos
MX2023010813A (es) Anticuerpos anti-alpp/alppl2 y conjugados de anticuerpo-farmaco.
BR112022026922A2 (pt) Anticorpo anti-lilrb1 e usos do mesmo
ZA202305072B (en) Cd1a antibodies and uses thereof